Park National Corp OH Boosts Holdings in AstraZeneca PLC (NASDAQ:AZN)

Park National Corp OH raised its position in AstraZeneca PLC (NASDAQ:AZN) by 0.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 154,132 shares of the company’s stock after acquiring an additional 911 shares during the quarter. Park National Corp OH’s holdings in AstraZeneca were worth $10,099,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Martin Investment Management LLC boosted its stake in AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares in the last quarter. Integrated Advisors Network LLC raised its holdings in shares of AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after buying an additional 13,860 shares during the last quarter. Creative Planning lifted its stake in shares of AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after buying an additional 16,692 shares during the period. Soros Fund Management LLC lifted its stake in shares of AstraZeneca by 8.2% during the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock worth $206,677,000 after buying an additional 201,233 shares during the period. Finally, Optas LLC grew its holdings in shares of AstraZeneca by 173.5% during the third quarter. Optas LLC now owns 15,570 shares of the company’s stock valued at $1,213,000 after buying an additional 9,877 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AZN has been the subject of a number of research analyst reports. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

Shares of AZN stock opened at $66.64 on Wednesday. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a market cap of $206.63 billion, a PE ratio of 31.89, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The business has a 50-day simple moving average of $66.42 and a 200-day simple moving average of $75.13.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the business earned $0.87 earnings per share. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. On average, equities analysts expect that AstraZeneca PLC will post 4.11 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.